Compare GRFS & S Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRFS | S |
|---|---|---|
| Founded | 1940 | 2013 |
| Country | Spain | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2B | 5.1B |
| IPO Year | 2006 | 2021 |
| Metric | GRFS | S |
|---|---|---|
| Price | $9.48 | $14.29 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 30 |
| Target Price | $10.15 | ★ $21.47 |
| AVG Volume (30 Days) | 467.0K | ★ 7.5M |
| Earning Date | 07-28-2022 | 03-11-2026 |
| Dividend Yield | ★ 1.54% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.64 | N/A |
| Revenue | ★ $8,821,017,248.00 | $955,646,000.00 |
| Revenue This Year | $5.36 | $24.53 |
| Revenue Next Year | $5.15 | $20.04 |
| P/E Ratio | $17.84 | ★ N/A |
| Revenue Growth | 7.31 | ★ 24.09 |
| 52 Week Low | $6.19 | $13.46 |
| 52 Week High | $11.14 | $25.24 |
| Indicator | GRFS | S |
|---|---|---|
| Relative Strength Index (RSI) | 57.30 | 46.67 |
| Support Level | $9.12 | $13.87 |
| Resistance Level | $9.30 | $15.39 |
| Average True Range (ATR) | 0.21 | 0.55 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 91.74 | 46.63 |
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.
SentinelOne is a cloud-based cybersecurity company specializing in endpoint protection. SentinelOne's primary offering is its Singularity platform that offers a single pane of glass for an enterprise to detect and respond to security threats attacking its IT infrastructure. The California-based firm was founded in 2013 and went public in 2021.